Bronislaw Edmund Masojada
Bronislaw Edmund Masojada's purchase track record
Bronislaw Edmund Masojada has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/6/2025 | BRO | $91K | -14.9% | -18.9% | +8.5% |
| 6/21/2023 | BRO | $263K | +11.4% | +5.3% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Brown & Brown Faces Mixed Analyst Views on Valuation. Brown & Brown is seeing diverging opinions from Wall Street analysts. Wells Fargo lowered its price target to $68, citing concerns about core business weakness, while TD Cowen initiated coverage with a higher target of $82. The stock currently trades near a key support level, reflecting a market weighing these conflicting assessments of the company's value.
Transaction History
| SPNT | ▲ Buy | Grant | 5,903 | $137K | 5/29/2026 | View on chart |
| BRO | ▲ Buy | Grant | 2,434 | $0 | 5/6/2026 | View on chart |
| BRO | ▲ Buy | Open Market | 1,000 | $91K | 8/6/2025 | View on chart |
| SPNT | ▲ Buy | Grant | 7,456 | $137K | 5/27/2025 | View on chart |
| BRO | ▲ Buy | Grant | 1,268 | $0 | 5/7/2025 | View on chart |
| SPNT | ▲ Buy | Grant | 10,528 | $137K | 5/21/2024 | View on chart |
| BRO | ▲ Buy | Grant | 1,407 | $0 | 5/8/2024 | View on chart |
| BRO | ▲ Buy | Open Market | 4,000 | $263K | 6/21/2023 | View on chart |
| SPNT | ▲ Buy | Grant | 14,929 | $137K | 6/15/2023 | View on chart |
| SPNT | ▲ Buy | Grant | 26,911 | $0 | 5/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SiriusPoint (SPNT) Valuation Questioned After Recent Price Rise
Recent market discussion has focused on whether SiriusPoint remains undervalued following a recent increase in its share price. The company currently trades with a low trailing P/E ratio of 5.7, which is significantly below the average analyst target of $28.75. This valuation gap has prompted investors to reassess the stock's position within its 52-week range of $17.39 to $26.50.
SiriusPoint (SPNT) Valuation Questioned After Recent Price Rise. Recent market discussion has focused on whether SiriusPoint remains undervalued following a recent increase in its share price. The company currently trades with a low trailing P/E ratio of 5.7, which is significantly below the average analyst target of $28.75. This valuation gap has prompted investors to reassess the stock's position within its 52-week range of $17.39 to $26.50.